tirzepatide cardiovascular Tirzepatide for Heart Failure in Patients with Obesity

Mechanisms of action, benefits, and risks of tirzepatide in CVDs

27.56

★★★★☆4.8 (126)

Effects of Tirzepatide on the Clinical Trajectory of Patients With Heart Failure, Preserved Ejection Fraction, and Obesity

27.60

★★★★★4.9 (98)

Tirzepatide goes beyond weight loss—supporting heart health, vascular function, and overall metabolic wellness. #Tirzepatide #HeartHealth #MetabolicSupport #Type2Diabetes #CardiovascularHealth #AmaneciaHealth

21.30

★★★★★5.0 (157)

In the SURPASS-CVOT head-to-head trial involving over 13,000 adults with T2D and ASCVD, tirzepatide (Mounjaro) matched dulaglutide in reducing major cardiovascular events (8% lower risk) and significantly cut all-cause mortality by 16%

25.71

★★★★★4.7 (84)

CARDIOVASCULAR EFFICACY OF TIRZEPATIDE IN PATIENTS WITH TYPE 2 DIABETES MELLITUS: AN INDIVIDUAL PARTICIPANT DATA META-ANALYSIS OF 8 RANDOMIZED CLINICAL TRIALS

27.36

★★★★★4.9 (203)

Cardiovascular Outcomes with Tirzepatide Compared with Dulaglutide in Patients with Type 2 Diabetes and Atherosclerotic Cardiovascular Disease

25.20

★★★★★5.0 (176)

❇️ Cardiovascular Outcomes with Tirzepatide versus Dulaglutide in Type 2 Diabetes 🟠BACKGROUND Tirzepatide, a dual incretin agonist of the glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide receptors, has favorable effects on

27.40

★★★★★4.8 (132)